iShares Biotechnology ETF Target of Unusually High Options Trading (NASDAQ:IBB)

iShares Biotechnology ETF (NASDAQ:IBB) saw unusually large options trading activity on Monday. Investors bought 66,590 put options on the stock. This is an increase of 1,205% compared to the average volume of 5,103 put options.

iShares Biotechnology ETF Price Performance

IBB stock opened at $133.39 on Wednesday. The company’s 50-day moving average price is $144.03 and its two-hundred day moving average price is $141.80. iShares Biotechnology ETF has a 12 month low of $117.28 and a 12 month high of $150.57.

iShares Biotechnology ETF Dividend Announcement

The firm also recently declared a dividend, which was paid on Monday, September 30th. Stockholders of record on Wednesday, September 25th were paid a $0.2005 dividend. The ex-dividend date was Wednesday, September 25th.

Institutional Trading of iShares Biotechnology ETF

Several large investors have recently bought and sold shares of IBB. Williams Financial LLC acquired a new position in iShares Biotechnology ETF in the 2nd quarter worth about $867,000. PVG Asset Management Corp acquired a new stake in iShares Biotechnology ETF in the second quarter valued at $415,000. Huntington National Bank raised its position in iShares Biotechnology ETF by 17.9% during the 3rd quarter. Huntington National Bank now owns 1,054 shares of the financial services provider’s stock worth $153,000 after purchasing an additional 160 shares during the last quarter. Concourse Financial Group Securities Inc. grew its position in shares of iShares Biotechnology ETF by 22.4% in the 2nd quarter. Concourse Financial Group Securities Inc. now owns 656 shares of the financial services provider’s stock valued at $90,000 after buying an additional 120 shares during the last quarter. Finally, Raymond James & Associates grew its position in shares of iShares Biotechnology ETF by 4.4% in the 2nd quarter. Raymond James & Associates now owns 189,766 shares of the financial services provider’s stock valued at $26,047,000 after buying an additional 7,931 shares during the last quarter. 62.45% of the stock is owned by institutional investors and hedge funds.

iShares Biotechnology ETF Company Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.